The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).
Young-Hyuck Im
No relevant relationships to disclose
Yeon Hee Park
No relevant relationships to disclose
Kyung Hae Jung
No relevant relationships to disclose
Seock-Ah Im
No relevant relationships to disclose
Joo Hyuk Sohn
No relevant relationships to disclose
Jungsil Ro
No relevant relationships to disclose
Sung-Bae Kim
No relevant relationships to disclose
Jin-Hee Ahn
No relevant relationships to disclose
Do Youn Oh
No relevant relationships to disclose
Sae-Won Han
No relevant relationships to disclose
Soohyeon Lee
No relevant relationships to disclose
In Hae Park
No relevant relationships to disclose
Keun-Seok Lee
No relevant relationships to disclose
Jee Hyun Kim
No relevant relationships to disclose
Seok Yun Kang
No relevant relationships to disclose
Moon Hee Lee
No relevant relationships to disclose
Hee Sook Park
No relevant relationships to disclose
Jin Seok Ahn
No relevant relationships to disclose